<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 123 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page122.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=123">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 123 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 123</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=123"><img src="../thumb/123.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>92 / 2020-04                                       Autacoids / Cardio-Vascular Agents - 6.2 / 6.3 / 7 / 7.1 / 7.1.1
                                                                   st
   ds., loc.reacts., sensat.of warmth/flush., hiccups, trans.asymptomat.  Interactions: Plasma lev.of pimozide/ astemizole & cisapride elev.  dos.giv.as 1  dos & futher.fract.of tot.dos.at 4-8 hr.interv. Each dos.
   incr.in aminotransferas., dizzin., trans vis.disturbs.  result.in poss.life threaten. reacts., plasma conc.of meds.metabol.   to be admin.by IV infus.over 10-20 mins. Assess. clinic.respons.bef.
   Special precautions: Rout.post-op N&V prophylax. not recomm.  through CYP3A4 poss.elev., plasma conc.of meds. metabol.through   giv.each addit.dos.
   where expectat.is slight, tot. dly.dos.of 8 mg not to be exceed.in mod./   CYP2C9 low., AUC of dexamethasone & methylprednisolone incr.,   Maint dos.in atrial fibrillat.: Bas.on % of peak body stores lost each
   sev. hepat.impairm., passes into breast milk of animals, safety & ef-  effic. of oral contracept.poss.reduc., plasma conc. of midazolam/  day through eliminat.using formula in prod.lit. Usual. 0,125 mg dly.
   fic.of post-op N&V treatm./ prophylax.in elderly not est., limit. info   other benzodiazep.poss.incr., plasma conc.incr.by CYP3A4 inhibit.,   in adults or 0,0625 mg or less dly. where incr.digox.sensitiv. shown.
   avail.on sev. ren.impairm., hepat.impairm., do not admin. in same   plasma conc. decr.by CYP3A4 induc., AUC & C max of both aprepitant   Neonates/ infts.& childr.up to 10 yrs: Sugg. dos .intend.as
   syringe/ infus.as other medicat., do not autoclav. amps., pts. exhibit.  & paroxetine decr., AUC of tolbutamide decr., AUC of both aprepi-  guide only. Reconsid.init.dos.& reduc. dos.advis.when Lanoxin tak.
   hypersens. reacts.to other select.5-HT3 recept.antagon., monit.subac.   tant & diltiazem incr.  in preced.2 wks. In the newborn,partic.the premat.inft. ren.clear. di-
   intest.obstruct.pts., phenylketonur.for rapitabs.  IVEMEND 150 mg, MSD [P/S]  minish. & observe suit.dos.reduct.over & above gen.dos.guidelines.
   ZOFRAN, (Sandoz) GSK [P/S]   Fosaprepitant                 Parenter.load.dos:. IV load.dos.based on 24 hr. period. Preterm.
                                                              neonates &lt;1,5 kg: 20 µg/kg. Preterm.neonates 1,5-2,5 kg:
   Ondansetron as hydrochlor.dihydrate.  Indications: Prev.of ac.(0-24 hrs) & delay.(&gt;24-120 hrs) N&V assoc.   30 µg/kg. Term neonates up to 2 yrs: 35 µg/kg. 2-5 yrs: 35 µg/
   Indications: Cytotox.chemother.& radiother. induc. N&V, prevent.&   with init.& rep.courses of high. to mod.emetogen.Ca chemother.in   kg. 5-10 yrs: 25 µg/kg.
   treatm.of postop N&V.        combinat. with other anti-emet. agents  Admin.in div.dos.with approx..half tot.dos.giv.as 1  dos & futher.fract.
                                                                                  st
   (S4) TABS, [P/S] X/5.10/332, 333.  (S4) LYOPHIL.POWD FOR SOL FOR INFUS., 45/5.7.2/0871  of tot.dos.at 4-8 hr.interv. Assess. clinic.respons.bef.giv.each addit.
   785814-019: 4 mg, 15, R852,43  723180-001: 150 mg, 1x10 ml vial, R986,93  dos. Each dos.to be admin.by IV infus.over 10-20 mins.
   785830-006: 8 mg, 15, R1345,41  Dosage: Admin.as part of regim.incl. corticoster. (dexamethasone)   Oral load.dos: Sched.based.on 24 hr.period. Preterm.neonates:
   (S4) INJ, [P/S] X/5.10/331, Y/5.10/170. 2 mg/ml.  x4 days & a 5-HT 3 antagon.on day 1.  &lt;1,5 kg: 25 µg/kg. Preterm. neonates 1,5-2,5 kg: 30 µg/kg. Term
   785806-008: 5x2 ml amps, R308,01  Day 1: 150 mg infus.over 20-30 mins.30 mins.prior to chemother.  neonates to 2 yrs: 45 µg/kg. 2-5 yrs: 35 µg/kg. 5-10 yrs: 25 µg/kg.
   785822-003: 5x4 ml amps, R616,04  Contraindications: Concom.pimozide/cisapride, pregn., lactat.,   Admin.load.dos.in div.dos.with approx.½ tot.dos. given as 1st dos
   (S4) ZYDIS DISPERS.TABS, 32/5.10/0461, 0462.  safety in paed.pts.not est.  & further fract.of tot.dos.given 4-8 hrly. Assess.clinic.respons.bef.
   862223 -008: 4 mg, 10, R397,21  Side effects: Candidias., staphylococc.infect., anaem., febrile neu-  each addit.dos.
   862231-019: 8 mg, 10, R804,88  tropen., decr.appet., polydips., anx., disorientat., euphor., dizzin., som-  Maint.dly.dos: Prem.neonates: 20% of 24 hr.IV or oral load.
   Dosage: Dissolv.Zydis tabs.on tong.& then swall  nol., cognit. disord., lethargy, dysgeus., conjunctivit., tinnit., palpit.,   dos. Term neonates & childr.up to 10 yrs.: 25% of 24 hr.IV or
   Emetogen.chemo-& radio ther: Adults: Bef. ther: 8 mg by slow   bradycard., CV disord., hot flush., hiccups, oropharyng.pain, sneez.,   oral load.dos.
   IVI/IMI immed.prior/ 8 mg orally 1-2 hrs.bef., follow.by 8 mg orally   cough, post-nas.drip, throat irrit., GI disords.incl.duod.ulc.perforat.&   Contraindications: Other digital.glycosid hypersens., ventric.
   12 hrly. Where delay./prolong.emesis expect.aft 1st 24 hrs.admin.   neutropen.colit., rash, acne, photosens.react., hyperhidros., seborrh.,   tachycard., tot./intermitt. complete heart block, 2nd degr.AV block,
   8 mg orally 2xdly.for up to 5 days aft.course.  skin les, prurit. rash, musc. spasms/weakn., dysuria, pollakiur., fatig.,   supraventric. dysrhythm.assoc.with access.AV pathway, hypertroph.
   Highly emetogen.chemother: Adults: Immed. bef.ther: 8 mg by   asthen., malais., oed., chest discomf., gait disturb., incr. ALT/AST, incr.  obstruct.cardiomyopathy, aort.stenos.
   slow IVI/IMI In pts.requir.high. dos.esp.those on high dos.cisplatin the   urine ouptput, decr.weight, glycosur., Stev.-Johns.syndr, loc.infus.site   Side effects: Common: CNS disturbs., dizzin., vis.disturbs., dys-
   follow.has prov.effect: 8 mg by slow IVI/IMI immed.bef. chemother,   reacts., incr. BP, erythema, flush., dysarthr., dyspn., hypoaesthes.,   rhythm., conduct.disturbs., bigeminy, trigeminy, PR prolongat., sinus
   follow.by 2 further IVI/IMI dos.of 8 mg 2-4 hrs apart/by const.infus.of   insomn., mios., sens.distrub., sub-ileus with high.dos., reduc.vis.  bradycard., N&V, diarrh., scarlatinif or urticar.skin rashes accompan.
   1 mg/hr x24 hrs. OR sngl.dos.of 16 mg dil.in 50-100 ml saline infus.  acuity, wheez., urticar., toxic epiderm.necrolys., hypersens.reacts.   by eosinophil. Uncomm: Depress. V.rare: Thrombocytopen., anorex.,
   over not less than 15 mins.immed.bef.chemother. Effic. may be en-  incl. anaphylact.reacts.  psychos., apathy, confus., headache, supraventric. tachydysrhythm.,
   hanc.by a sngl.IV dos.of dexamethasone phosph.20 mg 30-45 mins.  Warnings and special precautions: Sev.hepat. insuffic.(Child   atrial tachycard.with/-out block, nod.tachycard., ventric.dysrhythm.,
   prior to 1st Zofran dos. prior to chemother. Protect.against delay.em-  Pugh &gt;9), monit.concom.meds. metabol. prim.by/in part by CYP3A4   ventric.prem. contract., ST segm.depress., intestin.ischaem., intestin.
   esis aft. 1st 24 hrs: 8 mg orally 2x/day x5 days aft. course. Childr.over   caref., ther.not to be re-init.in pts.exper.hypersens.reacts., infus. site   necros., gynaecomast., fatig., malaise, weakn.
   4 yrs: 5 mg/m  IV over 15 mins. immed.bef.chemother.follow.by 4 mg   reacts., monit.chron.warfar.ther.with freq.INR close alternat. contra-  Warnings and special precautions: Rapid progress.of incomplete
         2
   orally every 12 hrs.x5 days has prov.effect.& well tol.  cept.dur.& 1 mnth follow.last dos., assess indiv. respons.bef.driv./  heart block, idioventric. escape rhythm.of complete heart block poss.
   Prevent.& treatm.of post-op N&V: Adults. Immed. prior to induct./  operat. machin., approx. 50% dos.reduct.of concom.oral dexameth-  suppress., poss./exacerbat.of sinus bradycard.or cause sinoatr.block
   post-op: 4 mg undil.IV.or IM. IV dose in not less than 30 seconds, pref.  asone to account for poss.drug interacts., refer to PI for co-admin.  in sinoatrial disords., aft.MI poss. incr.in myocard.O 2 demand with
   over 2-5 mins. Alternat.admin.16 mg orally 1 hr.prior to induct. Rep.  anti-emet. agents,  furth. ischaem., poss.dysrhythm.in hypoklaem.pts.aft.MI, avoid in
   dos.for pts.contin.to exper.N&V post-op not studied. Childr.2 yrs &   Interactions: Plasma lev.of pimozide & cisapride elev.result.in poss.  HF assoc.with card.amyloidos., avoid in myocardit. as vasoconstrict.
   over: 0,1 mg/kg up to max.4 mg by slow IV inj.prior to, at/aft.induct.  life threaten.reacts., plasma conc.of meds.metabol.through CYP3A4   poss.precipitat., poss. poor respons.in beri-beri unless thiamine defic.
   of anaesthes. Treatm.of est.post-op N&V: admin. 0,1 mg/kg upto   poss.elev., plasma conc. of meds.metabol.through CYP2C9 low., AUC   treat., avoid in constrict.pericardit.unless used to control ventric. rate
   max.4 mg by slow IVI. Rep.dos.in childr.who contin.to exp.N&V not   of dexamethasone & methylprednisolone incr., effic.of oral contra-  in atrial fibrillat./to improve systol. dysfunct., with concom.diuret./ACE
   studied,theref. should not to be given.  cept. poss. reduc., with oral aprepitant decr.in s(-) warfar. trough conc.  inhibit. ther. clinic.HF deteriorat.if Lanoxin withdrawn, elderly, reduc.
   Contraindications: Lactat., pregn., concom. apomorphine, con-  accompan.by prothromb.time (INR) decr., AUC of tolbutamide decr.,   ren.digox.clear., monit.ser.electrol.& ren. funct.periodic., reduc.dos.
   genit.long QT syndr.         plasma conc. of midazolam/other benzodiazep.poss.incr., plasma   if thyr.funct. subnorm., poss.incr.dos.in hyperthyroid.reduc.as condit.
   Side effects: Headache, flush., constip., hypersens. reacts., trans.  conc.incr.by CYP3A4 inhibit., plasma conc. decr. by CYP3A4 induc.,   comes und.control, malabsorpt.syndr./GI reconstruct. may req.larg.
   vis.disturbs., dizzin., invol. movem.disords., seiz., chest pain, arrythm.,   AUC of both aprepitant & diltiazem incr., AUC & C max of both aprepi-  dos., poss.PR interv. prolongat. & ST segm.depress.on ECG, myocard.
   hypotens., bradycard., loc.reacts.follow.inj.  tant & paroxetine decr.  sensitiv. incr.by hypokalaem./hypox./ hypomagnesaem./ hypercal-
   Special precautions: Do not admin.in same syringe/ infus.as other   caem.& sev.resp.dis., poss. vasoconstrict. with rapid IVI, IM inj.not
   medicat., tot.dly dos.of 8 mg not to be exceed.in mod./sev.hepat.im-  recomm., incr.risk of danger.dysrhythm.with dir. curr. cardiovers.in
   pairm., pts. with subac.intest.obstruct.to.be monit., phenylketonuria  pres.of Lanoxin, theref.discont x24 hrs. prior to elect.cardiovers.& in
                                7       CARDIO-VASCULAR       emerg.apply low. effect.energy, determine effs.bef.perform. tasks re-
   6.3    NK1 Antagonists               AGENTS                quir.concentrat., monit.ser.digox.conc. when doubt.interact.possibil.,
                                                              eval.risk.vs benef.in pregn., excret.in breast milk.
                                                              Tabs & PG tabs cont.lact.& elixir cont.sucrose
   EMEND, MSD [P/S]             7.1     Positive inotropic agents  Interactions: Incr.AV conduct.time with beta-adrenocept.block.
                                                              meds., incr.sensitiv.with agents caus. hypokalaem. eg.some diuret./
   Aprepitant                                                 Li/corticoster.& carbenoxolone, sennosides incr.toxic.risk.in HF pts.,
   Indications: Prophylax.of ac.& delay N&V assoc. with init.& rep.  incr.susceptibil.to suxamethonium exacerbat. hyperkalaem., ser.
   mod./high.emetogen.Ca chemother. in combinat.with other anti-  dysrhythm.with Ca admin.partic. rapid IV, labatinib incr.AUC, incr.
   emet. agents                 7.1.1   Cardiac glycosides    ren.excret.with bupropion, incr.ser.lev.with verapamil/ amiodarone/
   (S4) CAPS, A38/5.7.2/0626, 0627, 0625                      captopril/flecainide/prasozin/ propafenone/ quinidine/quinine/
   705301-001: 80 mg, 5, R1 644,95  LANOXIN, (Aspen Pharmacare: Pharma) Pharmacare[P/S]  spironolactone, tetracycl./ macrolide antibiot./gentamic./itraconaz.
   705302-001: 125 mg, 5, R1 644,95  Digoxin.                 /trimethoprim/ alprazolam/indomethac./ propatheline/ atorvastat./
   705303-001: Combipack (1x125 mg; 2x80 mg), 3, R805,19  Indications: Heart fail., atrial fibrill./flutter, supra ventric.arrhythm.  ciclospor./eporosten./ carvedilol/ ritonavir/dronedarone/ranolaz./
   Dosage: Admin.x3 days as part of regim.incl. corticoster.(dexametha-  (S3) TABS, [P/S] G2846.  telmisart.& ticagrelor, reduc.ser.lev.with antacids/ kaolin-pectin/
   sone) x4 days & a 5-HT 3 antagon. on day 1.  735752-001: 0,25 mg, 100, R46,88  bulk laxat./cholestyramine/ acarbose/ diphenoxylate, sulphasala-
   Recom.dos: 125 mg 1 hr prior to chemother.on day 1 & 80 mg once   735752-029: 0,25 mg, 120, R56,11  zine/neomycin /rifampicin/ cytostat./epinephr./salbutam./ pheny-
   dly on morn.of day 2 & 3.    735752-028: 0,25 mg, 500, R234,42  toin/ metoclopramide/penicillamine/St John’s Wort & supplement.
   Contraindications: Concom.pimozide/ astemizole or cisapride,   (S3) INJ, [P/S] G2848. 0,25 mg/ml.  parenter.nutrit., Ca chann. block.may incr./decr.or cause no change in
   safety in paed.pts.not est., no adeq.stud.in pregn., lactat.  735779-007: 5, R115,25  ser.lev., P-glycoprot.inhibit.incr.bld.conc.while P-glycoprot.induc.decr.
   Side effects: Candidias., staphylococc.infect., anaem., febrile neu-  (S3) PAED./GERIATR.TABS, [P/S] J/6.3/302.  bld.conc., incr.card.dysrhythm. risk with sympathomimet.
   tropen., decr.appet., polydips., anx., disorientat., euphor., CNS dis-  735760-004: 0,0625 mg, 100, R86,34
   ords,, conjunctivit., tinnit., palpit.,bradycard., CV disord., hot flush.,   735760-005: 0,0625 mg, 120, R103,62  PURGOXIN, (Aspen Pharmacare: Pharma) Pharmacare [P/S]
   hiccups, oropharyng.pain, sneez., cough, post-nas.drip, throat irrit., GI   (S3) PAED./GERIATR.ELIXIR, [P/S] G2847.  Digoxin.
   disords., rash, acne, photosens.react., hyperhidros., seborrh., skin les,   735744-009: 0,05 mg/ml, 50 ml, R87,01  Indications: Init.digitalisat./maint.ther.eg.auricul. fibrillat.& CHF.
   prurit. rash, musc. spasms/weakn., dysuria, pollakiur., fatig., asthen.,   735744-010: 0,05 mg/ml, 60 ml, R104,41  (S3) TABS. J/6.3/55
   malais., oed., chest discomf., gait disturb., incr.ALT/AST, Stev.-Johns.  Dosage: Toxic.is assoc.with ser.conc.&gt;2 ng/ml. To asses sympts.  758280-009: 0,25 mg, 100, R58,85
                                              +
   syndr, angioed., urticar., toxic epiderm.necrolys., hypersens. reacts.  consid.clinic.state tog.with ser.K /Ca & Mg lev./ thyroid funct./ECG   758280-017: 0,25 mg, 1 000, R588,50
   incl.anaphylact.reacts.      monit./hepat.& ren.funct.& pulse rate  Dosage: Init.2-3 tabs then 1-2 tabs.6 hrly., 4-6 tabs.over 24 hrs.norm.
   Warnings and special precautions: No clinic. data with sev.  Adults & childr.over 10 yrs: Indivual. Sugg. dos. intend.as init.  adeq. Maint.dose: 1 tab.1-2xdly.
   hepat.insuffic.(Child Pugh &gt;9), monit. concom.meds.metabol.prim.  guide only. Reconsid.init.dos.& reduc. dos.advis.when Lanoxin tak.in   Contraindications: Ventric.fibrillat.& hypertroph. obstruct.cardio-
   by/in part by CYP3A4 caref., caref.monit.prothromb.time (INR) with   preced.2 wks. Consid.diff.in bioavail.when switch.formulat. Reconsid.   myopathy unless there is sev.card. fail., Wolff-Parkinson-White syndr.
   chron.warfar.ther.in the 2 wk.period & partic. at 7-10 days follow.  dos.in elderly & reduc.ren.clear.  esp.if accompan. by atrial fibrillat., Ca salt inj.
   initiat.of 3 day regim. with each chemother.cycle, use altern.non   Rapid oral load (only for atrial fibrillat.): 0,75-1,5 mg in a sngl.  Side effects: GI disords., card.arrhythm., precipit. toxic reacts.if K-
   horm. back-up contracept.ther.dur.& for 1 mnth.follow. ther., consult   dos. If urgency less/toxic.risk incr. giv load.dos.in div.dos.6 hrs apart   deplet., allerg.& skin reacts., gynaecomast.& some oestrog.activ.,
   full prescrib.info of concom.anti-emet. agents., approx. 50% dos.  assess. clinic. respons.bef.giv.each addit.dos.  vis.disturbs. incl.col.disturbs.
   reduct.of concom. oral dexamethasone to account for poss. drug in-  Slow oral load: In chron.CF init.with desir.maint. dos.of 0,125 mg/  Special precautions: Heart block, ac.myocardit., advanc.HF, sev.
   teracts., approx.25% dos.reduct.of concom. IV methylprednisolone   day  pulm.dis., prev.card.glycosid.ther., monit.for digox.toxic., imp.ren.
   & approx.50% dos. reduct.of concom.oral methylprednisolone to ac-  Parenter.load: For treat.atrial dysrhythm. within preceed.2   funct., elderly, premat. infts., electrol.imbal., thyroid dysfunct., hy-
   count for poss.drug interacts., contains sucrose  wks: Tot.load.dos: 0,5-1 mg admin.in div.dos.with approx..half tot.  pokalaem./hypomagnesaem/hypercalcaem./ hypox. & hypothyroid.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page122.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page118.html">118</a>&nbsp;&nbsp;&nbsp;<a href="page119.html">119</a>&nbsp;&nbsp;&nbsp;<a href="page120.html">120</a>&nbsp;&nbsp;&nbsp;<a href="page121.html">121</a>&nbsp;&nbsp;&nbsp;<a href="page122.html">122</a>&nbsp;&nbsp;&nbsp;<a href="page123.html">123</a>&nbsp;&nbsp;&nbsp;<a href="page124.html">124</a>&nbsp;&nbsp;&nbsp;<a href="page125.html">125</a>&nbsp;&nbsp;&nbsp;<a href="page126.html">126</a>&nbsp;&nbsp;&nbsp;<a href="page127.html">127</a>&nbsp;&nbsp;&nbsp;<a href="page128.html">128</a>
             </td>
             <td width="35%"><a href="page124.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page124.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
